Articles

For the patients interviewed, the impacts of hereditary transthyretin amyloidosis were profound. Read More ›

Investigations of subclinical features in hATTR are warranted to understand the potential role of early disease-modifying treatment. Read More ›

Serum Transthyretin in the Management of TTR Amyloidosis
Justin L. Grodin, MD, MPH, Assistant Professor of Medicine, UT Southwestern Medical Center, Dallas, TX, explains the current and potentially future utilities of serum transthyretin (sTTR) as a biomarker in the management of transthyretin amyloidosis. Read More ›

The HELIOS-A study of vutrisiran in patients with hereditary transthyretin amyloidosis met the primary and all secondary end points. Read More ›

Diagnosis of this disease is often missed and still underdiagnosed, despite recent diagnostic improvements and the use of scintigraphy. Read More ›

The inclusion of patients who also have cardiac amyloidosis in clinical trials evaluating treatments for heart failure with preserved ejection fraction may help explain the underperformance of drugs that are effective in other forms of heart failure. Read More ›

] V122I TTR variant carrier status is associated with specific subclinical cardiac abnormalities in middle age. Read More ›


Setting Realistic Treatment Goals and Expectations for Patients with Transthyretin Amyloidosis
Ola Akinboboye, MD, MPH, MBA, Clinical Professor, Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health and Medical Director, Laurelton Heart Specialists PC (Rosedale, NY) and Clement C. Eiswirth, Jr., MD, FACC, Medical Director, Cardiomyopathy and Heart Failure Program, Ochsner Health, New Orleans, LA, highlight the importance of early diagnosis and realistic expectations for patients being treated for transthyretin amyloidosis. Read More ›

The ANDROMEDA study revealed a significant hematologic complete response rate in patients with newly diagnosed light chain amyloidosis treated with daratumumab plus hyaluronidase human-fihj. Read More ›

Page 10 of 14

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.